Wall Street brokerages forecast that Repligen Co. (NASDAQ:RGEN) will announce earnings of $0.20 per share for the current quarter, according to Zacks. Five analysts have provided estimates for Repligen’s earnings, with the highest EPS estimate coming in at $0.21 and the lowest estimate coming in at $0.18. Repligen reported earnings per share of $0.17 during the same quarter last year, which suggests a positive year-over-year growth rate of 17.6%. The company is expected to report its next earnings results on Tuesday, May 14th.
On average, analysts expect that Repligen will report full-year earnings of $0.83 per share for the current year, with EPS estimates ranging from $0.81 to $0.84. For the next year, analysts expect that the firm will post earnings of $1.00 per share, with EPS estimates ranging from $0.97 to $1.05. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that that provide coverage for Repligen.
Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Thursday, February 21st. The biotechnology company reported $0.21 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.21. The business had revenue of $51.90 million for the quarter, compared to the consensus estimate of $50.27 million. Repligen had a net margin of 8.56% and a return on equity of 5.51%. The company’s quarterly revenue was up 24.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.20 EPS.
A number of research analysts have issued reports on RGEN shares. Zacks Investment Research raised shares of Repligen from a “hold” rating to a “buy” rating and set a $55.00 price objective on the stock in a research report on Tuesday, December 25th. BidaskClub downgraded shares of Repligen from a “buy” rating to a “hold” rating in a research report on Wednesday, January 2nd. Finally, ValuEngine downgraded shares of Repligen from a “strong-buy” rating to a “buy” rating in a research report on Thursday, April 4th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $59.20.
In other Repligen news, CFO Jon Snodgres sold 1,875 shares of the company’s stock in a transaction dated Thursday, February 28th. The shares were sold at an average price of $58.88, for a total transaction of $110,400.00. Following the transaction, the chief financial officer now owns 26,821 shares in the company, valued at approximately $1,579,220.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Anthony Hunt sold 14,550 shares of the company’s stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $59.63, for a total transaction of $867,616.50. Following the transaction, the chief executive officer now owns 219,616 shares in the company, valued at approximately $13,095,702.08. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 48,437 shares of company stock worth $2,855,032. Company insiders own 1.40% of the company’s stock.
A number of institutional investors have recently added to or reduced their stakes in the stock. Huntington National Bank purchased a new stake in Repligen during the 1st quarter valued at approximately $25,000. First Hawaiian Bank purchased a new stake in Repligen during the 4th quarter valued at approximately $28,000. Enlightenment Research LLC purchased a new stake in Repligen during the 4th quarter valued at approximately $42,000. Parallel Advisors LLC grew its holdings in Repligen by 485.1% during the 4th quarter. Parallel Advisors LLC now owns 1,258 shares of the biotechnology company’s stock valued at $66,000 after buying an additional 1,043 shares in the last quarter. Finally, Bronfman E.L. Rothschild L.P. grew its holdings in Repligen by 16.8% during the 4th quarter. Bronfman E.L. Rothschild L.P. now owns 1,491 shares of the biotechnology company’s stock valued at $79,000 after buying an additional 214 shares in the last quarter. 91.18% of the stock is owned by institutional investors.
Repligen stock traded down $1.52 during mid-day trading on Friday, reaching $53.80. 23,519 shares of the company traded hands, compared to its average volume of 265,042. The company has a market cap of $2.44 billion, a P/E ratio of 73.70, a PEG ratio of 3.83 and a beta of 1.08. Repligen has a 52-week low of $36.41 and a 52-week high of $70.50.
Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.